Literature DB >> 2070813

Mitochondrial protein p26 BCL2 reduces growth factor requirements of NIH3T3 fibroblasts.

J C Reed1, H S Talwar, M Cuddy, G Baffy, J Williamson, U R Rapp, G J Fisher.   

Abstract

The BCL2 (B cell lymphoma/leukemia-2) proto-oncogene encodes a 26-kDa protein that has been localized to the inner mitochondrial membrane and that has been shown to enhance the survival of some types of hematopoietic cells. Here we show that NIH3T3 fibroblasts stably transfected with a BCL2 expression plasmid exhibit reduced dependence on competence-inducing growth factors (platelet-derived growth factor, PDGF; epidermal growth factor, EGF) for initiation of DNA synthesis. The importance of BCL2 for growth factor-induced proliferation of these cells was further confirmed by the useage of BCL2 antisense oligodeoxynucleotides. The mechanisms by which overexpression of p26 BCL2 contributes to fibroblast proliferation are unknown, but do not involve alterations in: (a) the production of inositol triphosphates (IP3), (b) PDGF-induced transient elevations in cytosolic Ca2+ ions, or (c) the activity of protein kinase C enzymes in these transfected cells. The results imply that changes in mitochondrial functions play an important role in the early stages of the cell cycle that render 3T3 cells competent to respond to the serum progression factors that stimulate entry into S-phase.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2070813     DOI: 10.1016/0014-4827(91)90374-4

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  11 in total

1.  Kinetics of retroviral production from the amphotropic ΨCRIP murine producer cell line.

Authors:  B Q Shen; M F Clarke; B O Palsson
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

Review 2.  Ca(2+) transfer from the ER to mitochondria: when, how and why.

Authors:  Rosario Rizzuto; Saverio Marchi; Massimo Bonora; Paola Aguiari; Angela Bononi; Diego De Stefani; Carlotta Giorgi; Sara Leo; Alessandro Rimessi; Roberta Siviero; Erika Zecchini; Paolo Pinton
Journal:  Biochim Biophys Acta       Date:  2009-03-31

3.  Overexpression of Bcl-2 in vascular endothelium inhibits the microvascular lesions of diabetic retinopathy.

Authors:  Timothy S Kern; Yunpeng Du; Casey M Miller; Denise A Hatala; Leonard A Levin
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

4.  Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin.

Authors:  S Krajewski; M Krajewska; J Ehrmann; M Sikorska; B Lach; J Chatten; J C Reed
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

5.  Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2.

Authors:  A J Wagner; M B Small; N Hay
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

6.  Bcl-2 expression in a primary leiomyosarcoma of the ovary: a case report.

Authors:  Klaus Bodner; Barbara Bodner-Adler; Klaus Czerwenka; Gernot Hudelist; Oliver Kimberger; Sepp Leodolter; Klaus Mayerhofer
Journal:  Wien Klin Wochenschr       Date:  2003-03-31       Impact factor: 1.704

7.  Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.

Authors:  V A Tron; S Krajewski; H Klein-Parker; G Li; V C Ho; J C Reed
Journal:  Am J Pathol       Date:  1995-03       Impact factor: 4.307

8.  Bcl-2 expression and other clinicopathologic parameters in uterine leiomyosarcoma.

Authors:  Klaus Bodner; Barbara Bodner-Adler; Oliver Kimberger; Klaus Czerwenka; Klaus Mayerhofer
Journal:  Wien Klin Wochenschr       Date:  2004-02-28       Impact factor: 1.704

9.  Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation.

Authors:  R A Screaton; L Z Penn; C P Stanners
Journal:  J Cell Biol       Date:  1997-05-19       Impact factor: 10.539

10.  Effect of 2-methoxyestradiol on SK-LMS-1 uterine leiomyosarcoma cells.

Authors:  Ji-Sun Lee; Changhwan Ahn; Hee Young Kang; Eui-Bae Jeung
Journal:  Oncol Lett       Date:  2017-05-12       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.